Literature DB >> 35035727

Long-term follow-up of diabetic patients with non-ST-segment elevation myocardial infarction.

Zhifeng Li1, Shaopeng Huang2, Rui Yang3, Jieyuan Li1, Guoqiang Chen1.   

Abstract

OBJECTIVE: Non-ST-segment elevation myocardial infarction (NSTEMI) is prevalent in patients with diabetes mellitus (DM). The long-term follow-up outcomes of this group of patients remain misunderstood. This study was aimed at investigating long-term follow-up outcomes of diabetic patients discharged with NSTEMI.
METHODS: All diabetic patients discharged with MI were recruited and followed up in this study. Patients who had elevated serum troponin, but no ST segment elevation were considered as NSTEMI. A structured follow-up was conducted at 3 months, 6 months, 12 months, and 24 months. Independent risk factors for all-cause and cardiovascular mortality were analyzed.
RESULTS: A total of 743 diabetic patients with MI enrolled for analysis, with 132 patients being recognized as NSTEMI. The mean age was 70.4±8.3 years. The mean follow-up was 21.3±6.1 months. NSTEMI (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.08-2.23), age ≥75 years (HR 1.17, 95% CI 1.04-1.31), hypertension (HR 1.51, 95% CI 1.03-2.21), heart failure (HF) (HR 3.23, 95% CI 2.28-4.57), and previous MI (HR 2.01, 95% CI 1.44-2.79) were independent risk factors for all-cause mortality. Administration of beta-blocker (HR 0.62, 95% CI 0.45-0.85) was associated with a lower incidence of all-cause mortality. Predictors for cardiovascular mortality included elderly, hypertension, HF, previous MI, and MI with atypical chest pain.
CONCLUSIONS: Multiple risk factors contribute to a higher incidence of composite outcomes in diabetic patients with MI. STEMI poses a greater threat to adverse events, which warrants more investigations. AJTR
Copyright © 2021.

Entities:  

Keywords:  Diabetes mellitus; mortality; myocardial infarction; non-ST-segment elevation

Year:  2021        PMID: 35035727      PMCID: PMC8748141     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  31 in total

1.  Can calcium channel blockers prior to tracheal intubation prevent myocardial ischaemia.

Authors:  T Nishikawa
Journal:  Anaesthesia       Date:  1992-07       Impact factor: 6.955

2.  Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.

Authors:  Manesh R Patel; Anita Y Chen; Eric D Peterson; L Kristin Newby; Charles V Pollack; Ralph G Brindis; C Michael Gibson; Neal S Kleiman; Jorge F Saucedo; Deepak L Bhatt; W Brian Gibler; E Magnus Ohman; Robert A Harrington; Matthew T Roe
Journal:  Am Heart J       Date:  2006-10       Impact factor: 4.749

Review 3.  Coronary Artery Disease and Type 2 Diabetes Mellitus.

Authors:  Ryo Naito; Katsumi Miyauchi
Journal:  Int Heart J       Date:  2017-07-14       Impact factor: 1.862

4.  The delayed activation wave in non-ST-elevation myocardial infarction.

Authors:  Tiesheng Niu; Peng Fu; Chenhong Jia; Yaling Dong; Chunyu Liang; Qian Cao; Zhiyong Yang; Rao Fu; Xingang Zhang; Zhaoqing Sun
Journal:  Int J Cardiol       Date:  2011-06-12       Impact factor: 4.164

5.  Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.

Authors:  María Cristina González-Cambeiro; Andrea López-López; Emad Abu-Assi; Sergio Raposeiras-Roubín; Carlos Peña-Gil; José García-Acuña; Ramón González-Juanatey
Journal:  Rev Port Cardiol       Date:  2016-11-17       Impact factor: 1.374

6.  Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome.

Authors:  Noora Ristiniemi; Juha Lund; Risto Tertti; Anders Christensson; Tuomo Ilva; Pekka Porela; Kari Pulkki; Kim Pettersson
Journal:  Clin Biochem       Date:  2012-02-27       Impact factor: 3.281

7.  Safety of Calcium-Channel Blockers During Radial Cardiac Catheterization in Patients With Acute Myocardial Infarction or Systolic Heart Failure.

Authors:  Barbara D Lawson; M Zubair Khan; Richard H Cooke; J Emilio Exaire; Luis A Guzman; Zachary M Gertz
Journal:  J Invasive Cardiol       Date:  2018-12-15       Impact factor: 2.022

8.  Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction.

Authors:  Basem Azab; Neeraj Shah; Meredith Akerman; Joseph T McGinn
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

9.  The relationship between fasting blood glucose variability and coronary artery collateral formation in type 2 diabetes patients with coronary artery disease.

Authors:  Gang Cheng; Hilda Mahmoudi; Binna Chokshi; Marlena Fernandez; Vahid Kazemi; Nader Lamaa
Journal:  Coron Artery Dis       Date:  2017-09       Impact factor: 1.439

10.  Cardioprotective actions of a new calcium channel blocker in acute myocardial ischemia.

Authors:  M E Brezinski; H Darius; A M Lefer
Journal:  Arzneimittelforschung       Date:  1986-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.